Sanofi's lixisenatide adds to effectiveness of insulin glargine in type 2 diabetes

Sanofi (Euronext: SAN) has presented new data suggesting that a fixed-ratio combination of lixisenatide and insulin glargine, known as iGlarLixi, helps more diabetes patients with type 2 diabetes to reach mealtime blood sugar targets than insulin glargine alone.

The French drug major is presenting new results from the pivotal Phase III study LixiLan-L at this week’s European Association for the Study of Diabetes (EASD) 52nd Annual Meeting.

Mike Baxter, consultant advisor to Sanofi Diabetes UK, said: “Blood glucose management in the UK is among the worst in Europe with, on average, people with type 2 diabetes having the highest blood glucose levels compared to nine other developed countries.